Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Non-Alcoholic Steatohepatitis (NASH) Drugs market report explains the definition, types, applications, major countries, and major players of the Non-Alcoholic Steatohepatitis (NASH) Drugs market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Immuron
AstraZeneca
Horizon Pharma
Gilead
Novo Nordisk
Intercept Pharmaceuticals
Galmed Pharmaceuticals
Conatus Pharmaceuticals
Enzo Biochem
Genfit
By Type:
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc
By End-User:
Hospital Pharmacy
Online Provider
Retail Pharmacy
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Outlook to 2028- Original Forecasts
-
2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Non-Alcoholic Steatohepatitis (NASH) Drugs Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market- Recent Developments
-
6.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market News and Developments
-
6.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Deals Landscape
7 Non-Alcoholic Steatohepatitis (NASH) Drugs Raw Materials and Cost Structure Analysis
-
7.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Raw Materials
-
7.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Price Trend of Key Raw Materials
-
7.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Suppliers of Raw Materials
-
7.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Rate of Raw Materials
-
7.5 Non-Alcoholic Steatohepatitis (NASH) Drugs Cost Structure Analysis
-
7.5.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Raw Materials Analysis
-
7.5.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Labor Cost Analysis
-
7.5.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Manufacturing Expenses Analysis
8 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Import and Export Analysis (Top 10 Countries)
-
8.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Export by Region (Top 10 Countries) (2017-2028)
9 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Vitamin E & Pioglitazone Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Obeticholic Acid (OCA) Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Elafibranor Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Selonsertib & Cenicriviroc Consumption and Growth Rate (2017-2022)
-
9.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Pharmacy Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Online Provider Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Retail Pharmacy Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Non-Alcoholic Steatohepatitis (NASH) Drugs Market Analysis and Outlook till 2022
-
10.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.2.2 Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.2.3 Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.3.2 UK Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.3.3 Spain Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.3.4 Belgium Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.3.5 France Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.3.6 Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.3.7 Denmark Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.3.8 Finland Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.3.9 Norway Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.3.10 Sweden Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.3.11 Poland Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.3.12 Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.3.13 Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.4.2 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.4.3 India Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.4.4 South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.4.5 Pakistan Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.4.6 Bangladesh Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.4.7 Indonesia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.4.8 Thailand Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.4.9 Singapore Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.4.10 Malaysia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.4.11 Philippines Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.4.12 Vietnam Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.5.2 Colombia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.5.3 Chile Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.5.4 Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.5.5 Venezuela Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.5.6 Peru Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.5.7 Puerto Rico Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.5.8 Ecuador Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.6.2 Kuwait Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.6.3 Oman Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.6.4 Qatar Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.6.5 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.6.6 United Arab Emirates Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.7.2 South Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.7.3 Egypt Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.7.4 Algeria Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
-
10.8.2 New Zealand Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)
11 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Competitive Analysis
-
11.1 Immuron
-
11.1.1 Immuron Company Details
-
11.1.2 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
11.1.4 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 AstraZeneca
-
11.2.1 AstraZeneca Company Details
-
11.2.2 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
11.2.4 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Horizon Pharma
-
11.3.1 Horizon Pharma Company Details
-
11.3.2 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
11.3.4 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Gilead
-
11.4.1 Gilead Company Details
-
11.4.2 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
11.4.4 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Novo Nordisk
-
11.5.1 Novo Nordisk Company Details
-
11.5.2 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
11.5.4 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Intercept Pharmaceuticals
-
11.6.1 Intercept Pharmaceuticals Company Details
-
11.6.2 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
11.6.4 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Galmed Pharmaceuticals
-
11.7.1 Galmed Pharmaceuticals Company Details
-
11.7.2 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
11.7.4 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Conatus Pharmaceuticals
-
11.8.1 Conatus Pharmaceuticals Company Details
-
11.8.2 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
11.8.4 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Enzo Biochem
-
11.9.1 Enzo Biochem Company Details
-
11.9.2 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
11.9.4 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Genfit
-
11.10.1 Genfit Company Details
-
11.10.2 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
11.10.4 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
11.10.5 Recent Research and Development Strategies
12 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Outlook by Types and Applications to 2028
-
12.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Vitamin E & Pioglitazone Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Obeticholic Acid (OCA) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Elafibranor Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Selonsertib & Cenicriviroc Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Online Provider Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Retail Pharmacy Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Non-Alcoholic Steatohepatitis (NASH) Drugs Market Analysis and Outlook to 2028
-
13.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.2.2 Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.2.3 Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.3.2 UK Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.3.3 Spain Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.3.4 Belgium Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.3.5 France Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.3.6 Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.3.7 Denmark Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.3.8 Finland Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.3.9 Norway Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.3.10 Sweden Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.3.11 Poland Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.3.12 Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.3.13 Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.4.2 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.4.3 India Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.4.4 South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.4.8 Thailand Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.4.9 Singapore Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.4.11 Philippines Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.5.2 Colombia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.5.3 Chile Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.5.4 Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.5.6 Peru Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.6.3 Oman Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.6.4 Qatar Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.7.2 South Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.7.3 Egypt Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.7.4 Algeria Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Non-Alcoholic Steatohepatitis (NASH) Drugs
-
Figure of Non-Alcoholic Steatohepatitis (NASH) Drugs Picture
-
Table Global Non-Alcoholic Steatohepatitis (NASH) Drugs Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Non-Alcoholic Steatohepatitis (NASH) Drugs Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Vitamin E & Pioglitazone Consumption and Growth Rate (2017-2022)
-
Figure Global Obeticholic Acid (OCA) Consumption and Growth Rate (2017-2022)
-
Figure Global Elafibranor Consumption and Growth Rate (2017-2022)
-
Figure Global Selonsertib & Cenicriviroc Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Pharmacy Consumption and Growth Rate (2017-2022)
-
Figure Global Online Provider Consumption and Growth Rate (2017-2022)
-
Figure Global Retail Pharmacy Consumption and Growth Rate (2017-2022)
-
Figure Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption by Country (2017-2022)
-
Table North America Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption by Country (2017-2022)
-
Figure United States Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption by Country (2017-2022)
-
Figure Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure UK Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Spain Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Belgium Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure France Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Denmark Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Finland Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Norway Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Sweden Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Poland Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Table APAC Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption by Country (2017-2022)
-
Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Thailand Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Singapore Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Philippines Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Table South America Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption by Country (2017-2022)
-
Figure Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Colombia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Chile Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Peru Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Table GCC Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption by Country (2017-2022)
-
Figure Bahrain Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Oman Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Qatar Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Table Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption by Country (2017-2022)
-
Figure Nigeria Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Egypt Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Algeria Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Table Oceania Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption by Country (2017-2022)
-
Figure Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)
-
Table Immuron Company Details
-
Table Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
Table Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
Table AstraZeneca Company Details
-
Table AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
Table AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
Table Horizon Pharma Company Details
-
Table Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
Table Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
Table Gilead Company Details
-
Table Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
Table Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
Table Novo Nordisk Company Details
-
Table Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
Table Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
Table Intercept Pharmaceuticals Company Details
-
Table Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
Table Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
Table Galmed Pharmaceuticals Company Details
-
Table Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
Table Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
Table Conatus Pharmaceuticals Company Details
-
Table Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
Table Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
Table Enzo Biochem Company Details
-
Table Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
Table Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
Table Genfit Company Details
-
Table Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Main Business and Markets Served
-
Table Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product Portfolio
-
Figure Global Vitamin E & Pioglitazone Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Obeticholic Acid (OCA) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Elafibranor Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Selonsertib & Cenicriviroc Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Online Provider Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Retail Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast by Country (2022-2028)
-
Table North America Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast by Country (2022-2028)
-
Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast by Country (2022-2028)
-
Figure Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
